Epigenomics' Q1 Revenues Drop 5 Percent

May 10, 2017

|

NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Epigenomics' Q1 Revenues Drop 5 Percent

To read the full story....

Breaking News

FDA Issues Emergency Use Authorization for University of Nebraska Medical Center Coronavirus Test

Oxford Immunotec Shares Rise Sharply on Report of $400M Acquisition Offer

Medix Biochemica Acquires US Firms EastCoast Bio, Biostride

HHS Releases Data Reporting Guidance for Labs Performing SARS-CoV-2 Testing

Opti Medical Systems Gets CE Mark for Coronavirus Test Kit

AACC Revises Guidance on Management of Point-of-Care Testing

Featured White Papers

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

Labs Launching Employer SARS-CoV-2 Testing Programs as Businesses Reopen

HHS Releases Data Reporting Guidance for Labs Performing SARS-CoV-2 Testing

CDC Develops Test for Simultaneous Detection of COVID-19, Flu

Beset by COVID-19 Pandemic, Europe Searches for Right Test Mix for Diagnosis, Surveillance

Roche Garners FDA Emergency Use Authorization for Elecsys IL-6 Test in COVID-19 Patients

Sponsorships